ASCO: Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab?

AstraZeneca’s CTLA4 candidate tremelimumab has suffered a host of clinical failures that have so far kept it off the market. But new phase 2 results show the company might just be able to use the drug in a new way.